SecBot SecBot
6-K ·Filed Jul 17, 2026

SNY

Sanofi
BULLISH
Impact 6/10
Horizonimmediate Processed4mo ago SEC0001193125-26-306689
Notable filing: 6-K
Actionable Insight ▲ Bullish

Monitor early prescription data and physician adoption of the OBI formulation over the next 2-4 quarters. Key competitive risk is Johnson & Johnson's Darzalex (daratumumab), which also has SC formulations. Any market share shifts will be visible in Sanofi's quarterly oncology segment reporting.

DirectionBullish
Confidencehigh
Horizonimmediate

Drug in focus

SNY drug pipeline →

Sarclisa

● Neutral Named in this 6-K
Impact
Phase
Approved / marketed (IV since 2020, SC since 2026); additional Phase 2/3 studies completed or ongoing.
Time to market
Already approved and marketed: IV formulation since March 2020; subcutaneous 'Sarclisa Escena' formulation approved July 9, 2026.
Next catalyst
None dated

What to watchWatch Sanofi's quarterly earnings disclosures for Sarclisa/Sarclisa Escena sales growth and launch uptake of the new subcutaneous on-body-injector form, plus any data presentations from completed isatuximab trials (a Phase 3 IV-vs-SC study finished primary completion Jan 30, 2026).

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$44.66
T+0 close · Jul 17, 2026 · via day close
Latest settled
−11.02%
T+60 · $39.74
Vs SPY
−15.70%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 17 $44.66entry
  2. T+1 · 4mo ago −1.52%α −1.36% · $43.98
  3. T+5 · 4mo ago −2.91%α −2.22% · $43.36
  4. T+20 · 3mo ago −2.10%α −6.55% · $43.72
  5. T+60 · 5w ago −11.02%α −15.70% · $39.74
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Sanofi announced FDA approval of subcutaneous Sarclisa Escena (isatuximab-irfc) for all existing multiple myeloma indications, making it the first anticancer treatment administered via an on-body injector. The approval, supported by the Phase 3 IRAKLIA study showing non-inferior efficacy with shorter administration time and fewer infusion reactions, strengthens Sarclisa's competitive positioning and may drive adoption through improved patient convenience.

Key Facts

  • FDA approved subcutaneous Sarclisa Escena across all existing IV indications for multiple myeloma
  • First anticancer treatment to be administered via an on-body injector (CirCLIQ OBI)
  • IRAKLIA Phase 3 study demonstrated non-inferior ORR (71.1% SC vs 70.5% IV) with significantly fewer systemic administration reactions (1.5% vs 25%)
  • Sarclisa has been prescribed to over 70,000 patients worldwide and is approved in nearly 60 countries

Financial Impact

Positive but unquantified; the SC formulation may expand Sarclisa's addressable patient population and improve treatment convenience, potentially increasing market share against competitors like Darzalex. No specific revenue guidance provided.

revenue

Risk Factors

  • Competition from Darzalex SC (J&J) which already has a subcutaneous formulation
  • Adoption may be slower if providers are reluctant to adopt new administration devices
  • No incremental efficacy benefit over IV formulation; differentiation is purely convenience-based

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
55% bullish (29 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001193125-26-306689
Document: d106024d6k.htm0001193125-26-306689
Document: 0001193125-26-306689-index-headers.html0001193125-26-306689
Document: 0001193125-26-306689-index.html0001193125-26-306689
Document: 0001193125-26-306689.txt0001193125-26-306689

Track record

15 reports on SNY

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +7.69% at T+60 after the Aug 17, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $47.47 to $48.43 Now $48.39 +1.94% ▲ +2.02% +2.94% vs SPY
  2. Oct 30, 202617d ago 6-K Bullish 6/10 Entry $44.34 to $47.04 Now $48.39 +9.13% ▲ +6.09% +8.79% vs SPY
  3. Oct 26, 202621d ago SC 13G/A Neutral 2/10 Entry $41.89 to $45.33 Now $48.39 +15.52% ▲ +8.21% +10.20% vs SPY
  4. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $41.79 to $44.34 Now $48.39 +15.79% ▲ +6.10% +7.36% vs SPY
  5. Oct 1, 20266w ago 6-K Mixed 5/10 Entry $40.67 to $40.23 Now $48.39 +18.98% ▼ −1.08% −2.38% vs SPY
  6. Sep 17, 20268w ago 6-K Neutral 4/10 Entry $43.14 to $40.94 Now $48.39 +12.17% ▼ −5.10% −5.95% vs SPY
  7. Aug 31, 202611w ago Court Ruling Neutral 2/10 Entry $44.37 to $42.85 Now $48.39 +9.06% ▼ −3.43% −3.51% vs SPY
  8. Aug 17, 202613w ago Court Ruling Bullish 4/10 Entry $44.97 to $46.02 Now $48.39 +7.61% ▲ +2.33% +2.54% vs SPY
  9. Aug 12, 202613w ago Court Ruling Neutral 2/10 Entry $43.78 to $45.15 Now $48.39 +10.53% ▲ +3.13% +5.09% vs SPY
  10. Jul 31, 202615w ago Court Ruling Bullish 5/10 Entry $42.95 to $43.48 Now $48.39 +12.67% ▲ +1.23% −0.79% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens Wed (11h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 17, 2026